Explore
Validate
Learn
Western blot
Blocking/NeutralizingAntibody data
- Antibody Data
- Antigen structure
- References [9]
- Comments [0]
- Validations
- Blocking/Neutralizing [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF874 - Provider product page
- Provider
- R&D Systems
- Product name
- Human IL-10 R beta Antibody
- Antibody type
- Polyclonal
- Description
- Antigen Affinity-purified. Detects human IL-10 R beta in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant human (rh) IL-20 R alpha , rhIL-10 R, and rhIL-20 R beta is observed.
- Reactivity
- Human
- Host
- Goat
- Conjugate
- Unconjugated
- Antigen sequence
Q08334- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Submitted references IFN-λ4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling.
Trisomy 21 consistently activates the interferon response.
HCV infection selectively impairs type I but not type III IFN signaling.
Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines.
Biological activity of interleukins-28 and -29: comparison with type I interferons.
Cutting edge: IL-26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-10 receptor 2.
Cutting edge: IL-26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-10 receptor 2.
IL-28, IL-29 and their class II cytokine receptor IL-28R.
Abnormal interleukin 10Ralpha expression contributes to the maintenance of elevated cyclooxygenase-2 in non-small cell lung cancer cells.
Obajemu AA, Rao N, Dilley KA, Vargas JM, Sheikh F, Donnelly RP, Shabman RS, Meissner EG, Prokunina-Olsson L, Onabajo OO
Journal of immunology (Baltimore, Md. : 1950) 2017 Dec 1;199(11):3808-3820
Journal of immunology (Baltimore, Md. : 1950) 2017 Dec 1;199(11):3808-3820
Trisomy 21 consistently activates the interferon response.
Sullivan KD, Lewis HC, Hill AA, Pandey A, Jackson LP, Cabral JM, Smith KP, Liggett LA, Gomez EB, Galbraith MD, DeGregori J, Espinosa JM
eLife 2016 Jul 29;5
eLife 2016 Jul 29;5
HCV infection selectively impairs type I but not type III IFN signaling.
Chandra PK, Bao L, Song K, Aboulnasr FM, Baker DP, Shores N, Wimley WC, Liu S, Hagedorn CH, Fuchs SY, Wu T, Balart LA, Dash S
The American journal of pathology 2014 Jan;184(1):214-29
The American journal of pathology 2014 Jan;184(1):214-29
Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines.
Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, Sabat R, Wolk K
Genes and immunity 2009 Dec;10(8):702-14
Genes and immunity 2009 Dec;10(8):702-14
Biological activity of interleukins-28 and -29: comparison with type I interferons.
Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M
Cytokine 2005 Jul 21;31(2):109-18
Cytokine 2005 Jul 21;31(2):109-18
Cutting edge: IL-26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-10 receptor 2.
Sheikh F, Baurin VV, Lewis-Antes A, Shah NK, Smirnov SV, Anantha S, Dickensheets H, Dumoutier L, Renauld JC, Zdanov A, Donnelly RP, Kotenko SV
Journal of immunology (Baltimore, Md. : 1950) 2004 Feb 15;172(4):2006-10
Journal of immunology (Baltimore, Md. : 1950) 2004 Feb 15;172(4):2006-10
Cutting edge: IL-26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-10 receptor 2.
Sheikh F, Baurin VV, Lewis-Antes A, Shah NK, Smirnov SV, Anantha S, Dickensheets H, Dumoutier L, Renauld JC, Zdanov A, Donnelly RP, Kotenko SV
Journal of immunology (Baltimore, Md. : 1950) 2004 Feb 15;172(4):2006-10
Journal of immunology (Baltimore, Md. : 1950) 2004 Feb 15;172(4):2006-10
IL-28, IL-29 and their class II cytokine receptor IL-28R.
Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM
Nature immunology 2003 Jan;4(1):63-8
Nature immunology 2003 Jan;4(1):63-8
Abnormal interleukin 10Ralpha expression contributes to the maintenance of elevated cyclooxygenase-2 in non-small cell lung cancer cells.
Heuze-Vourc'h N, Zhu L, Krysan K, Batra RK, Sharma S, Dubinett SM
Cancer research 2003 Feb 15;63(4):766-70
Cancer research 2003 Feb 15;63(4):766-70
No comments: Submit comment
Supportive validation
- Submitted by
- R&D Systems (provider)
- Main image
- Experimental details
- IL-10 Inhibition of IL-1 beta secretion and Neutralization by Human IL-10 R beta Antibody. Recombinant Human IL-10 (Catalog # 217-IL) inhibits IL-1 beta secretion in LPS-activated human peripheral blood mononuclear cells (PBMC) in a dose-dependent manner (orange line), as measured by the Human IL-1 beta/IL-1F2 Quantikine ELISA Kit (Catalog # DLB50). IL-1 beta secretion inhibited by Recombinant Human IL-10 (0.25 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL-10 R beta Antigen Affinity-purified Polyclonal Antibody (Catalog # AF874). The ND50 is typically 2-6 µg/mL in the presence of LPS (0.25 ng/mL).
